Gene therapy in diabetes

Self/Nonself - Immune Recognition and Signaling

Volumn 1, Issue 3, 2010, Pages 165-175

  Wong, Mary S ^a   Hawthorne, Wayne J ^a   Manolios, Nicholas ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Autoimmunity; Core peptide; Drug delivery; Gene therapy; Lentivirus; Type 1 diabetes

Indexed keywords

BETA GALACTOSIDASE; CALCIUM PHOSPHATE; CORE PEPTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ELONGATION FACTOR 1ALPHA; EXENDIN 4; FK 506 BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMATE DECARBOXYLASE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; LEPTIN; LIPOSOME; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; PEPTIDE; PROINSULIN; RIBOZYME; SCATTER FACTOR; SOMATOMEDIN C; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; ZINC FINGER PROTEIN;

ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; CONTACT ALLERGY; DENDRITIC CELL; DIABETES MELLITUS; DRUG EFFECT; EPENDYMA CELL; EPITHELIUM CELL; GENE TRANSFER; GENETIC ENGINEERING; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CELL; NONHUMAN; NONVIRAL GENE THERAPY; PANCREAS ISLET TRANSPLANTATION; PATHOPHYSIOLOGY; REVIEW; STEM CELL; STREPTOZOCIN DIABETES; VIRAL GENE THERAPY;

EID: 78049278409     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.1.3.12643     Document Type: Review

References (102)

1. Klein R. Diabetic retinopathy. Annu Rev Public Health 1996; 17:137-58.
2. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. An update. Hypertension 1995; 26:869-79.
3. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003; 26:1553-79.
4. McCulloch D. Classification of diabetes mellitus and genetic diabetic syndromes. In: Rose B, ed. UpToDate. Waltham, MA: UpToDate 2007.
5. Glaser B. Type 2 diabetes: hypoinsulinism, hyperinsulinism or both? PLoS Med 2007; 4:148.
6. Lernmark A, Barmeier H, Dube S, Hagopian W, Karlsen AE, Markholst H, et al. Molecular analysis of the pathogenesis of beta-cell destruction in insulin-dependent diabetes mellitus. West J Med 1990; 153:499-502.
7. Harris MI, Robbins DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994; 17:1337-40.
8. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990; 33:561-8.
9. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995; 18:1557-65.
10. Chong JW, Craig ME, Cameron FJ, Clarke CF, Rodda CP, Donath SM, et al. Marked increase in type 1 diabetes mellitus incidence in children aged 0-14 yr in Victoria, Australia from 1999 to 2002. Pediatr Diabetes 2007; 8:67-73.
11. Chung ST, Perue GG, Johnson A, Younger N, Hoo CS, Pascoe RW, et al. Predictors of hyperglycaemic crises and their associated mortality in Jamaica. Diabetes Res Clin Pract 2006; 73:184-90.
12. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 2001; 44:3-15.
13. Quinn M, Fleischman A, Rosner B, Nigrin DJ, Wolfsdorf JI. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr 2006; 148:366-71.
14. Duncan G. Prevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey 1999-2002. Archives of Pediatrics & Adolescent Medicine 2006; 160:523-8.
15. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664-72.
16. Liese AD, D'Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118:1510-8.
17. Lipton RB, Drum M, Burnet D, Rich B, Cooper A, Baumann E, et al. Obesity at the onset of diabetes in an ethnically diverse population of children: what does it mean for epidemiologists and clinicians? Pediatrics 2005; 115:553-60.
18. Durruty P, Ruiz F, Garcia de los Rios M. Age at diagnosis and seasonal variation in the onset of insulin-dependent diabetes in Chile (Southern hemisphere). Diabetologia 1979; 17:357-60.
19. Elamin A, Omer MI, Zein K, Tuvemo T. Epidemiology of childhood type I diabetes in Sudan 1987-90. Diabetes Care 1992; 15:1556-9.
20. Felner EI, Klitz W, Ham M, Lazaro AM, Stastny P, Dupont B, et al. Genetic interaction among three genomic regions creates distinct contributions to early-and late-onset type 1 diabetes mellitus. Pediatr Diabetes 2005; 6:213-20.
21. International Diabetes Federation. Diabetes Atlas, Third Edition 2006.
22. Bell RA, Mayer-Davis EJ, Beyer JW, D'Agostino RB Jr, Lawrence JM, Linder B, et al. Diabetes in non- Hispanic white youth: prevalence, incidence and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32:102-11.
23. Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999; 22:1066-70.
24. Krolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987; 317:1390-8.
25. Mamoulakis D, Galanakis E, Bicouvarakis S, Paraskakis E, Sbyrakis S. Epidemiology of childhood type I diabetes in Crete 1990-2001. Acta Paediatr 2003; 92:737-9.
26. Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84-91.
27. International Diabetes Institute. AusDiab Followup Study Report 2005.
28. National Center for Chronic Disease Prevention and Health Promotion [USA]. Diabetes Projects.
29. Rosenbauer J, Herzig P, von Kries R, Neu A, Giani G. Temporal, seasonal and geographical incidence patterns of type I diabetes mellitus in children under 5 years of age in Germany. Diabetologia 1999; 42:1055-9.
30. Silink M. Childhood diabetes: a global perspective. Horm Res 2002; 57:1-5.
31. Qiao Q, Osterholm AM, He B, Pitkaniemi J, Cordell HJ, Sarti C, et al. A genome-wide scan for type 1 diabetes susceptibility genes in nuclear families with multiple affected siblings in Finland. BMC Genet 2007; 8:84.
32. Levitsky L, Misra M. Epidemiology, presentation and diagnosis of type 1 diabetes mellitus in children and adolescents. In: Rose B, ed. UpToDate. Waltham, MA: UpToDate 2007.
33. Roche EF, Lewy H, Hoey HM, Laron Z. Differences between males and females in the seasonality of birth and month of clinical onset of disease in children with type 1 diabetes mellitus in Ireland. J Pediatr Endocrinol Metab 2003; 16:779-82.
34. Zalloua PA, Terwedow H, Shbaklo H, Halaby G, Xu X, Azar ST. Host and environmental factors defining the epidemiology of type 1 diabetes mellitus in a group of Lebanese children and young adults. J Pediatr Endocrinol Metab 2003; 16:759-69.
35. Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716-24.
36. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-9.
37. Gronski MA, Weinem M. Death pathways in T cell homeostasis and their role in autoimmune diabetes. Rev Diabet Stud 2006; 3:88-95.
38. Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001; 108:1247-52.
39. Radillo O, Nocera A, Leprini A, Barocci S, Mollnes TE, Pocecco M, et al. Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Clin Immunol Immunopathol 1996; 79:217-23.
40. Wucherpfennig KW, Eisenbarth GS. Type 1 diabetes. Nat Immunol 2001; 2:767-8.
41. Hussain A, Vincent M. Diabetes Mellitus, Type 1. In: Ziel F, Talavera F, Schalch D, Cooper M, Griffing G, eds 2007.
42. Bresson D, von Herrath M. Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 2007; 6:315-22.
43. American Diabetes Association. Prescribing physical activity for the management of cardiovascular disease and diabetes. Diabetes and Cardiovascular Disease Review 2005; 1-12.
44. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 2006; 8:343-75.
45. Levine F. Gene therapy for diabetes: strategies for beta-cell modification and replacement. Diabetes Metab Rev 1997; 13:209-46.
46. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy-a review. Stem Cells Dev 2004; 13:133-45.
47. Leibowitz G, Beattie GM, Kafri T, Cirulli V, Lopez AD, Hayek A, et al. Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes 1999; 48:745-53.
48. Yoon JW, Jun HS. Recent advances in insulin gene therapy for type 1 diabetes. Trends Mol Med 2002; 8:62-8.
49. Bobisse S, Zanovello P, Rosato A. T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. Expert Opin Biol Ther 2007; 7:893-906.
50. Mitanchez D, Doiron B, Chen R, Kahn A. Glucose-stimulated genes and prospects of gene therapy for type I diabetes. Endocr Rev 1997; 18:520-40.
51. Becker TC, BeltrandelRio H, Noel RJ, Johnson JH, Newgard CB. Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. Enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. J Biol Chem 1994; 269:21234-8.
52. Csete ME, Benhamou PY, Drazan KE, Wu L, McIntee DF, Afra R, et al. Efficient gene transfer to pancreatic islets mediated by adenoviral vectors. Transplantation 1995; 59:263-8.
53. Sigalla J, David A, Anegon I, Fiche M, Huvelin JM, Boeffard F, et al. Adenovirus-mediated gene transfer into isolated mouse adult pancreatic islets: normal beta-cell function despite induction of an anti-adenovirus immune response. Hum Gene Ther 1997; 8:1625-34.
54. Barbu AR, Bodin B, Welsh M, Jansson L, Welsh N. A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans. Diabetologia 2006; 49:2388-91.
55. Fernandes JR, Duvivier-Kali VF, Keegan M, Hollister- Lock J, Omer A, Su S, et al. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol 2004; 13:191-200.
56. Giannoukakis N, Rudert WA, Robbins PD, Trucco M. Targeting autoimmune diabetes with gene therapy. Diabetes 1999; 48:2107-21.
57. He Z, Wang F, Kumagai-Braesch M, Permert J, Holgersson J. Long-term gene expression and metabolic control exerted by lentivirus-transduced pancreatic islets. Xenotransplantation 2006; 13:195-203.
58. Efrat S. Prospects for gene therapy of insulin-dependent diabetes mellitus. Diabetologia 1998; 41:1401-9.
59. Halban PA, Kahn SE, Lernmark A, Rhodes CJ. Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? Diabetes 2001; 50:2181-91.
60. Moore HP, Walker MD, Lee F, Kelly RB. Expressing a human proinsulin cDNA in a mouse ACTH-secreting cell. Intracellular storage, proteolytic processing and secretion on stimulation. Cell 1983; 35:531-8.
61. Selden RF, Skoskiewicz MJ, Russell PS, Goodman HM. Regulation of insulin-gene expression. Implications for gene therapy. N Engl J Med 1987; 317:1067-76.
62. Tian J, Lei P, Laychock SG, Andreadis ST. Regulated insulin delivery from human epidermal cells reverses hyperglycemia. Mol Ther 2008; 16:1146-53.
63. Lei P, Ogunade A, Kirkwood KL, Laychock SG, Andreadis ST. Efficient production of bioactive insulin from human epidermal keratinocytes and tissue-engineered skin substitutes: implications for treatment of diabetes. Tissue Eng 2007; 13:2119-31.
64. Zhang Y, Yao L, Shen K, Xu M, Zhou P, Yang W, et al. Genetically engineered K cells provide sufficient insulin to correct hyperglycemia in a nude murine model. Acta Biochim Biophys Sin (Shanghai) 2008; 40:149-57.
65. Olson DE, Campell AG, Porter MH, Freeman KG, Kelso E, Flatt WP, et al. Hepatic insulin gene therapy normalizes diurnal fluctuation of oxidative metabolism in diabetic BB/Wor rats. Mol Ther 2008; 16:1235-42.
66. Ren B, O'Brien BA, Swan MA, Koina ME, Nassif N, Wei MQ, et al. Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy. Diabetologia 2007; 50:1910-20.
67. Hsu PY, Kotin RM, Yang YW. Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes. Pharm Res 2008; 25:1460-8.
68. Fodor A, Harel C, Fodor L, Armoni M, Salmon P, Trono D, et al. Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach. Diabetologia 2007; 50:121-30.
69. Koizumi M, Nagai K, Kida A, Kami K, Ito D, Fujimoto K, et al. Forced expression of PDX-1 induces insulin production in intestinal epithelia. Surgery 2006; 140:273-80.
70. Xu J, Lu Y, Ding F, Zhan X, Zhu M, Wang Z. Reversal of diabetes in mice by intrahepatic injection of bone-derived GFP-murine mesenchymal stem cells infected with the recombinant retrovirus-carrying human insulin gene. World J Surg 2007; 31:1872-82.
71. Shternhall-Ron K, Quintana FJ, Perl S, Meivar-Levy I, Barshack I, Cohen IR, et al. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 2007; 28:134-42.
72. Niu L, Xu YC, Dai Z, Tang HQ. Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. World J Gastroenterol 2008; 14:4209-15.
73. Soltani N, Kumar M, Glinka Y, Prud'homme GJ, Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 2007; 14:981-8.
74. Panakanti R, Mahato RI. Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm Res 2009; 26:587-96.
75. Georgiou HM, Brady JL, Silva A, Lew AM. Genetic modification of an islet tumor cell line inhibits its rejection. Transplant Proc 1997; 29:1032-3.
76. Holm P, Rydlander B, Luthman H, Kockum I. Interaction and association analysis of a type 1 diabetes susceptibility locus on chromosome 5q11-q13 and the 7q32 chromosomal region in Scandinavian families. Diabetes 2004; 53:1584-91.
77. Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J Clin Endocrinol Metab 2005; 90:4904-11.
78. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198:63-9.
79. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102:516-26.
80. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998; 160:2684-91.
81. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 1995; 181:559-68.
82. Corbett JA, Wang JL, Misko TP, Zhao W, Hickey WF, McDaniel ML. Nitric oxide mediates IL-1beta-induced islet dysfunction and destruction: prevention by dexamethasone. Autoimmunity 1993; 15:145-53.
83. McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 1996; 211:24-32.
84. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, et al. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186:1193-200.
85. Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 2008; 127:176-87.
86. Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, Hartnett M, et al. Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Clin Immunol 2008; 129:195-201.
87. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000; 165:1102-10.
88. Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, et al. CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses. Diabetes 2007; 56:809-17.
89. Bregenholt S, Wang M, Wolfe T, Hughes A, Baerentzen L, Dyrberg T, et al. The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. Scand J Immunol 2003; 57:432-8.
90. Sadeghi H, Bregenholt S, Wegmann D, Petersen JS, Holmgren J, Lebens M. Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo. Immunology 2002; 106:237-45.
91. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91:10795-9.
92. Denes B, Yu J, Fodor N, Takatsy Z, Fodor I, Langridge WH. Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses. Mol Biotechnol 2006; 34:317-27.
93. Grey ST, Arvelo MB, Hasenkamp W, Bach FH, Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J Exp Med 1999; 190:1135-46.
94. Klein D, Ricordi C, Pugliese A, Pastori RL. Inhibition of Fas-mediated apoptosis in mouse insulinoma betaTC-3 cells via an anti-Fas ribozyme. Hum Gene Ther 2000; 11:1033-45.
95. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 2000; 7:2015-22.
96. Kojima S, Asakawa A, Amitani H, Sakoguchi T, Ueno N, Inui A, et al. Central leptin gene therapy, a substitute for insulin therapy to ameliorate hyperglycemia and hyperphagia and promote survival in insulin-deficient diabetic mice. Peptides 2009; 30:962-6.
97. Manolios N, Bonifacino JS, Klausner RD. Transmembrane helical interactions and the assembly of the T cell receptor complex. Science 1990; 249:274-7.
98. Manolios N, Collier S, Taylor J, Pollard J, Harrison LC, Bender V. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997; 3:84-8.
99. Huynh NT, Ffrench RA, Boadle RA, Manolios N. Transmembrane T-cell receptor peptides inhibit B-and natural killer-cell function. Immunology 2003; 108:458-64.
100. Amon MA, Ali M, Bender V, Chan YN, Toth I, Manolios N. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta 2006; 1763:879-88.
101. Manolios N, Ali M, Amon M, Bender V. Therapeutic Applications of Transmembrane T and Natural Killer Cell Receptor Peptides. In: Sigalov A, ed. Multichain Immune Recognition Receptor Signalling: From Spatiotemporal Organization to Human Disease: Landes Bioscience 2007; 208-19.
102. Mahnke K, Qian Y, Knop J, Enk AH. Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat Biotechnol 2003; 21:903-8.